Intravitreal Conbercept for Idiopathic Choroidal Neovascularization in Nursing Women

Shao, Zheyi; Li, Shanshan; Yu, Xuechen; Wang, Jiawei; Liu, Heng; Zhang, Ying; Huang, Chao; Zhou, Fang; Li, Jianqiao

doi:10.1089/bfm.2021.0097

Cited by 1 publication

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the significance of this is unclear, since conventional infant formula milk does not contain VEGF. For conbercept, an anti-VEGF agent frequently used in China, n = 2/3 patients studied did not experience a significant drop in VEGF levels in breast milk [ 4 ]. There were no data on serum concentrations of anti-VEGF nor reports of neurodevelopmental evaluations in these children.…”

Section: Discussionmentioning

confidence: 99%

“…There are even less data on the extent to which intravitreal anti-VEGF agents transfer to breast milk, and the potential consequences for breastfed infants. Women who defer anti-VEGF treatment until after delivery may therefore prefer to forego breastfeeding due to concerns about potential effects on their child [ 4 ]. Breastfeeding carries both short-term and long-term benefits in terms of nutrition, immunity, cognitive development, and limiting the risk of developing chronic systemic diseases [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intravitreal anti-vascular endothelial growth factor injections in pregnancy and breastfeeding: a case series and systematic review of the literature

Ong,

Kiire,

Frise

et al. 2023

Eye

View full text Add to dashboard Cite

Introduction Anti-vascular endothelial growth factor (anti-VEGF) agents may occasionally need to be considered for sight-threatening macular pathology in pregnant and breastfeeding women. This is controversial due to the dearth of data on systemic side effects for mother and child. We aimed to expand the evidence base to inform management. Methods Retrospective case series of pregnant and breastfeeding women treated with intravitreal anti-VEGF injections at Oxford Eye Hospital between January 2015 and December 2022. In addition, we conducted a systematic review and combined eligible cases in a narrative synthesis. Results We treated six pregnant women with anti-VEGF for diabetic macular oedema(DMO) (n = 5) or choroidal neovascularisation (CNV) (n = 1). Four received ranibizumab whilst two (not known to be pregnant) received aflibercept. Patients known to be pregnant underwent counselling by an obstetric physician. Five pregnancies resulted in live births. Combining our cases with those previously published, treatment of 41 pregnant women (42 pregnancies) are reported. Indications for treatment included CNV (n = 28/41,68%), DMO (n = 7/41,17%) and proliferative diabetic retinopathy (n = 6/41,15%). Bevacizumab (n = 22/41,54%) and ranibizumab (n = 17/41,41%) were given more frequently than aflibercept (n = 2/41,5%). Many (n = 16/41,40%) were unaware of their pregnancy when treated. Most pregnancies resulted in live births (n = 34/42,81%). First trimester miscarriages (n = 5/42,12%) and stillbirths (n = 3/42,7%) mostly occurred in women with significant risk factors. Conclusion Intravitreal anti-VEGF injections may not necessarily compromise obstetric outcomes, although clear associations cannot be drawn due to small numbers and confounders from high rates of first trimester miscarriages in general and inherently high-risk pregnancies. It may be worth considering routinely investigating pregnancy and breastfeeding status in women of childbearing age prior to each injection, as part of anti-VEGF treatment protocols.

show abstract

Section: Discussionmentioning

confidence: 99%